US5648251A - Method of transduction of cells with retroviral vectors - Google Patents
Method of transduction of cells with retroviral vectors Download PDFInfo
- Publication number
- US5648251A US5648251A US08/450,914 US45091495A US5648251A US 5648251 A US5648251 A US 5648251A US 45091495 A US45091495 A US 45091495A US 5648251 A US5648251 A US 5648251A
- Authority
- US
- United States
- Prior art keywords
- cells
- sup
- vector
- transduction
- retroviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10051—Methods of production or purification of viral material
Definitions
- This invention relates to the purification of retroviral vectors. More particularly, this invention relates to a method of large scale purification of retroviral vector particles whereby one obtains improved recovery of retroviral vector particles from a culture of retroviral vector producer cells.
- the diseases under investigation involving the use of retroviral vectors for gene therapy include various types of cancer, genetic diseases (including adenosine deaminase deficiency, cystic fibrosis, and familial hypercholesteremia), and infectious diseases, specifically AIDS (Rosenberg et al., N. Engl. J. Med., Vol. 323, pgs. 570-578 (1990); Anderson, et al., Hum. Gene. Ther., Vol. 1, pgs. 331-362 (1990); Grossman, et al., J. Lab. Clin. Med., Vol. 119, pgs.
- AIDS Rosenberg et al., N. Engl. J. Med., Vol. 323, pgs. 570-578 (1990)
- retroviral vectors In order to facilitate clinical applications of retroviral-mediated human gene transfer, retroviral vectors must be of high titer and free of detectable replication-competent retroviruses. However, it has been difficult to obtain large quantities of such retroviral vectors.
- FIG. 1 Number of cells and vector titers of PA317/G1Na.40 producer cells grown in 75-cm 2 flasks at different temperatures.
- FIG. 2 Effect of temperature on viral particles per cell during 12 days of culture.
- PA317/G1Na.40 producer cells were grown in 75-cm 2 flasks at 37 C., 34 C. and 32 C. Medium was changed every 24 hr. Cell number and vector titer were determined daily.
- FIG. 3 A total of 1 ⁇ 10 6 cells in a 24-well plate were transduced with and without centrifugation (spun) at 2,500 rpm at 32° C. for 90 min. Cells were incubated overnight at 32° C. Three days after transduction the cells were prepared for PCR and FACS analyses.
- Cells were harvested and suspended in basal DMEM containing 0.1 ⁇ g/ml rhodamine-123. Cells were incubated at 37° C. for 20 min., then centrifuged at 1,500 rpm for 10 min. Cells were resuspended in basal medium and effluxed at 37° C. for 45 min. Flow cytometry was performed by EPICS cytometer (Coulter).
- a method of purifying retroviral vector particles comprises culturing retroviral vector producer cells, which are capable of generating retroviral vector particles.
- a supernatant containing retroviral vector particles then is obtained from the culture of retroviral vector producer cells.
- the supernatant then is clarified, and then the clarified supernatant is concentrated after clarification.
- the concentrated supernatant then is contacted with a precipitation agent to form a precipitate containing the retroviral vector particles.
- the precipitate is recovered, and the recovered precipitate is suspended in a liquid.
- the retroviral vector particles are separated from the remainder of the precipitate by density gradient centrifugation. The separated retroviral vector particles then are recovered.
- purified retroviral vectors particles means a preparation of retroviral particles containing at least 80% by weight, preferably at least 85% by weight, and more preferably at least 90% by weight, of retroviral vector particles.
- the retroviral vector producer cells may be cultured in any of a variety of monolayer culture systems. Such producer cells may be cultured in T-flasks, roller bottles, or bioreactors. The cells may be cultured in any acceptable culture medium such as, for example, AIM-V medium (Gibco BRL, Grand Island, N.Y.) containing 5% fetal bovine serum, or Dulbecco's modified Eagle medium (DMEM) with high glucose (4.5 g/l) supplemented with 10% heat-inactivated fetal bovine serum.
- AIM-V medium Gibco BRL, Grand Island, N.Y.
- DMEM Dulbecco's modified Eagle medium
- the producer cell line may be formed by transducing an appropriate packaging cell line with retroviral vectors.
- packaging cell lines which may be transduced include, but are not limited to, the PA317, PE501, ⁇ -2, ⁇ -AM, PA12, T19-14X, VT-19-17-H2, ⁇ RE, ⁇ CRIP, GPL, GP+E-86, GP+envAm12, and DAN cell lines.
- the vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO 4 precipitation.
- the cells generally may be cultured at a temperature of from about 32° C. to about 37° C. Most preferably, the cells are cultured at a temperature of about 32° C. At 32° C., the vector particles have a half-life of up to about 48 hours.
- the viral supernatant which is obtained from the culture of retroviral vector producer cells, and which may have a titer of, for example, from about 10 6 to about 10 7 CFU/ml, may be clarified by passing the supernatant through a filter means, such as a nominal type filter unit.
- the filter may have a pore size of from about 0.2 ⁇ to about 5.0 ⁇ , preferably from about 0.8 ⁇ to about 1.5 ⁇ . Most preferably, the filter has a pore size of about 1.2 ⁇ .
- the clarified viral supernatant then may be concentrated by passing the clarified viral supernatant through a tangential flow filtration system.
- the membrane in such system has a 300,000 molecular weight cutoff.
- Such a system may reduce the volume of supernatant containing retroviral vector particles by about 16 to 25 times, with vector recovery being at least 90%.
- An example of a tangential flow filtration system which may be employed in accordance with the present invention is a Millipore Pellicon tangential flow filtration system (Millipore, Bedford, Mass.) with a PLMK000C5 cassette (5 square feet, 300,000 NMWL).
- the system also may be equipped with a pump to exert a low membrane feed pressure of 5 psi.
- Such a concentrated viral supernatant may have a vector recovery of greater than 95% compared with the amount of vector present prior to concentration, and a vector titer of from about 10 7 to about 10 8 CFU/ml.
- the concentrated viral supernatant then is contacted with a precipitation agent.
- the precipitation agent is a polyalkylene glycol, such as, for example, polyethylene glycol.
- the viral supernatant and the precipitation agent are centrifuged at a speed of from about 8,000 ⁇ g to about 10,000 ⁇ g to pellet precipitated material, which then is recovered.
- Such precipitate contains the retroviral vector particles.
- the recovered precipitate is suspended in a liquid, such as a buffer.
- the retroviral vector particles are separated from the remainder of the precipitate by density gradient centrifugation.
- the suspended precipitate is subjected to sucrose gradient ultracentrifugation (discontinuous or preferably linear). More preferably, the ultracentrifugation is effected at a speed of from about 100,000 ⁇ g to about 120,000 ⁇ g.
- the retroviral vector particles are recovered.
- Vector recovery may be greater than 95%, and vector titer may be from about 10 9 to about 10 10 CFU/ml.
- An example of purifying viral supernatant by polyethylene glycol precipitation and sucrose gradient centrifugation is described in Syrewicz, et al., Appl. Microbiol., Vol. 24, pgs. 488-494 (1972), incorporated herein by reference.
- the above purification steps enable one to recover an increased amount of retroviral vector particles.
- the resulting preparation containing the retroviral vector particles is free of components which may compete with the retroviral vector particles for binding sites located on target cells to which the retroviral vector particles may bind and infect.
- Such components include free gp70 protein and empty viral particles.
- the retroviral vector particles recovered from the centrifugation step may be lyophilized and saved for future use.
- Such lyophilization may be carried out by adding to the retroviral vector supernatant solutions of glucose and/or sorbitol and gelatin in phosphate buffered saline. The samples then maybe frozen in a dry ice/acetone bath and then placed in a freeze dryer.
- the lyophilized retroviral vector particles may be reconstituted by adding an equal volume of sterile water. After reconstitution, vector recovery may be greater than 90%, and vector titer may be from about 10 9 to about 10 10 CFU/ml.
- the purified retroviral vector particles are used to transduce cells in vivo or ex vivo for purposes of gene therapy.
- the inventors have developed a novel preferred transduction method, which they call spin transduction.
- the particles, suspended in a pharmaceutically acceptable carrier, are contacted with the cells to be transduced, and the mixture is centrifuged for a sufficient period of time to permit transduction.
- the mixture is centrifuged at 1,000-4,000 rpm, preferably at 2,000-3,000 rpm, and most preferably at about 2,500 rpm for a period of time from about 30 minutes to 3 hours, preferably 1 to 2 hours, and most preferably about 90 minutes.
- the spin transduction is done at a tempreature of 15° C. to 37° C., preferably 20° C. to 35° C., and most preferably 32° C. This method leads to a 3- to 15-fold increase in transduction efficiency, depending on the type of cells transduced.
- NIH-3T3 TK-cells were seeded at 1 ⁇ 10 5 cells/well of a six-well tissue culture plate (Becton Dickinson, Lincoln Park, N.J.) and incubated at 37° C. in 5% CO 2 .
- serial ten-fold dilutions of vector specimen in medium containing 8 ⁇ g/ml Polybrene were added to the target cells and incubated at 32° C. for an additional 24 hours.
- the medium was removed and replaced with medium containing 800 ⁇ g/ml G418. Plates were incubated at 37° C. in 5% CO 2 .
- plates were refed with medium containing 800 ug/ml G418.
- colonies were stained with methylene blue and the vector titer was calculated as the number of colony forming units (cfu) per ml.
- the following producer cell lines were formed by transducing retroviral vectors including various desired genes and promoters (sometime hereinafter referred to as Gene 1, Gene 2, Promoter 1, and Promoter 2) into the PA317 amphotropic retrovirus packaging cell line (Miller, et al, Mol. Cell. Biol., Vol. 6, pgs. 2895-2902 (1986); Miller, et al., Biotechniques, Vol 7, pgs. 980-990 (1989), incorporated herein by reference), were formed by standard transduction techniques.
- the producer cell lines are given in Table I below:
- Producer cell line PA317/G1Na.40 is described in Miller, Curr. Top. Microbiol. Immunol., Vol. 158, pgs. 1-24(1992), incorporated herein by reference.
- Producer cell line PA317/LASN is described in Hock, et al., Blood, Vol. 74, pgs. 876-881 (1989), incorporated herein by reference.
- Producer cell line PA317/L1XSN is described in Palmer, et al., Blood, Vol. 73, pgs. 438-445 (1989), incorporated herein by reference.
- PA317/G1Na.40 producer cells (2 ⁇ 10 6 cells) were inoculated in 75-cm 2 flasks and were incubated at 37° C., 34° C., and 32° C. in 5% CO 2 to determine the effect of incubation temperature on vector titer. The medium was changed every day.
- the amphotropic retroviral vectors were assayed by a G418 selection method using NIH-3T3 TK - cells as target cells.
- NIH-3T3 TK - cells were seeded at 1 ⁇ 10 5 cells/well of a six-well tissue culture plate (Becton Dickinson, Lincoln Park, N.J.) and incubated at 37° C. in 5% CO 2 .
- serial ten-fold dilutions of vector specimen in medium containing 8 ⁇ g/ml Polybrene were added to the target cells and incubated at 32° C. for an additional 24 hr.
- the medium was removed and replaced with medium containing 800 ⁇ g/ml G418.
- FIG. 1 The results are shown in FIG. 1.
- Cells grown at 37° C., 34° C., and 32° C. achieved 100% confluence on days 5, 6, and 8, respectively. Days 5, 6, and 8 also showed the highest vector titers for each of the three temperatures. Retroviral vector titers increased as temperature decreased. The highest vector titer of 1-day-old supernatant was always obtained from cells incubated at 32° C., 8.5 ⁇ 10 6 cfu/ml, and remained at that approximate level for 5 days. Cells incubated at 37° C. showed the lowest titer over 7 days. In the experiment shown in FIG. 1, the maximum titer difference between 32° C. and 37° C. was 1.5 logs on day 8. Vector from cells incubated at 34° C.
- the number of vector particles per cell was calculated by dividing the number of vector particles per milliliter determined in a standard titer assay by the number of cells from viability counts. As shown in FIG. 2, the 32° C. and 34° C. incubation temperatures showed a maximum of six vector particles per cell compared with a maximum of two vector particles per cell at 37° C. under the conditions of these calculations.
- PA317/G1Na.40 cells were grown in 75-cm 2 flasks and roller bottles with and without 5% CO 2 in air.
- the titer of vector supernatants cultivated under both conditions revealed similar titers at the three incubation temperatures studied (data not shown).
- the results of these studies and those with other vectors suggest that endogenous CO 2 from the cells support the cell growth and vector production without 5% exogenous CO 2 .
- Producer cells were easily adapted to grow in 850-cm 2 roller bottles. Cells maintained maximum confluence for at least 2 weeks. PA317/G1Na.40 and PA317/LT12SN.40 producer cells were grown in roller bottles and incubated at 37° C., 34° C., and 32° C. After the cells reached confluence, the medium was harvested daily. The vector titers shown in Table II below represent the titers reached after 100% confluence.
- the vector titer of 2-day-old supernatants from PA317/G1Na.40 and PA317/LT12SN.40 were approximately two times and four times higher than that of 1-day-old supernatants, respectively.
- the above results from 2-day-old supernatant collection at 32° C. incubation also were demonstrated using several of the other producer cell lines. Increased titers at lower temperature may be partially due to decreased vector inactivation at the lower temperature.
- roller bottles of different surface areas were compared for vector yield.
- the vector titer from supernatants of PA317/G1Na.40 and PA317/G1 ⁇ Gsvna.29 producer cell lines from a pleated roller bottle of 1,700-cm 2 surface area were approximately twice that of the 850-cm 2 roller bottle (Table IV).
- the number of cells counted at the end of the 2-week culture from a 1,700-cm 2 roller bottle was approximately twice that counted from the 850-cm 2 roller bottle (data not shown), suggesting that the vector yield per cell did not differ in the pleated and unpleated bottles.
- the highest virus titer achieved was from a 2-day-old PA317/G1Na.40 supernatant from the pleated-type roller bottle incubated at 32° C., 1 ⁇ 10 6 cfu/ml. This has been repeated two times. Twenty-one of 22 different retroviral vector producer cells increased titers by a 2-day-old supernatant at 32° C. incubation. Vector LASN was the exception in this study.
- the viral supernatant was harvested from the roller bottle by aspiration or pouring into a collection bottle. Immediately thereafter, the supernatant was clarified by pumping the supernatant through a 1.2 ⁇ nominal type polypropylene filter (Sartorius) to remove any debris and cells.
- Vector supernatants from PA317/G1Na.40, PA317/LT12SN.40, and PA317/G1NaSvAd.24 producer cells were concentrated using the Millipore Pellicon tangential flow filtration system (Millipore, Bedford, Mass.) with a PLMK000C5 cassette (5 square feet, 300,000 NMWL). A pump was used to exert a low membrane feed pressure of 5 psi. Concentration was achieved within 30 minutes. To ensure high vector recovery, it is necessary to maximize the surface area of the membrane and minimize supernatant circulation with a low membrane feed pressure. As shown in Table V below, the volume of the supernatant was reduced from 16 to 25 times, and the vector titer increased from 15 to 24 times. Vector recovery ranged from 91% to 96%.
- the concentrated viral supernatant (from about 100 ml to about 200 ml) was mixed with a 1/10 volume of 4M NaCl on ice while stirring. Polyethylene glycol was added (8% w/v) slowly and stirred in ice for 3 hours. The precipitate was collected by centrifugation at 8,000 ⁇ g for 15 minutes and resuspended in 0.01M tris (hydroxymethyl) aminomethane hydrochloride (TNE) pH7.5, 0.1M NaCl, and 0.001M ethylenediamine tetracetic acid (i.e., at from about 1/100 to 1/25 of the original supernatant volume).
- TNE tris (hydroxymethyl) aminomethane hydrochloride
- the suspension was layered on a discontinuous sucrose gradient (20% and 55% w/w) in TNE and centrifuged in a Beckman SW-40Ti rotor at 100,000 ⁇ g for 2 hours at 4° C.
- virus band was observed.
- the virus band was collected by inserting a 21-gauge hypodermic needle into the centrifuge tube, and diluted ten-fold with TNE and stored at -70° C.
- Vector recovery was greater than 95% and vector titer was at least 10 9 CFU/ml.
- Lyophilization of retroviral vectors was performed using a Model Freeze Mobil Lyophilizer (Virtis, Gardiner, N.Y.).
- the additives, glucose, sorbitol, and gelatin were prepared as 50%, 50%, and 25% solutions, respectively, in phosphate-buffered saline (PBS).
- PBS phosphate-buffered saline
- the solutions were filtered through 0.22 ⁇ m filters.
- Aliquots of glucose (1 ml), sorbitol (1 ml), or sorbitol with gelatin (1 ml) were added to the viral supernatant (19 ml) derived from PA317/G1Na.40 producer cells.
- the samples were frozen quickly in 1.0 ml or 20 ml aliquots in a dry ice/acetone bath and placed in a freeze-dryer.
- the lyophilized material was stored at 4° C. Samples were reconstituted with an equal volume of sterile water.
- Retroviral vectors were preserved after lyophilization and retained relatively high transducibility. As shown in Table VI below, samples without additives showed the lowest recovery rate, 21%. Specimens supplemented with glucose, sorbitol, or gelatin demonstrated a relatively low recovery rate (from 48% to 61%). The combination of glucose or sorbitol with gelatin, however, demonstrated a higher vector recovery rate (from 64% to 83%). The viral titer was from 2 ⁇ 10 6 cfu/ml to 3 ⁇ 10 6 cfu/ml after lyophilization.
- NIH3T3 TK - cells were seeded at 1 ⁇ 10 5 cells/well in a six-well plate as an adherent target cell line and incubated at 37° C. overnight to yield approximately a 60% confluent monolayer.
- a 10-fold serial dilution of vector supernatants (10 4 , 10 -5 , and 10 -6 ) containing 8 ⁇ g/ml Polybrene were added in duplicate to appropriate wells on day 2.
- the six-well plate was centrifuged at 2,500 rpm for 90 min. at 32° C. by using a plate holder in a Beckman GS-6KR centrifuge (Beckman, Fullerton, Calif.). After centrifugation, the plate was incubated at 32° C. overnight.
- HUT 78 cells a human T-cell leukemia line, as a suspension target cell line, were transduced with an amphotrophic vector PA317/G1MD1-15 which carried the MDR1 gene encoding p-glycoprotein (Endicott, et al., Ann. Rev. Biochem., Vol. 58, pgs 137-171 (1989)).
- HBSS Hank's balanced salt solution
- PCR polymerase chain reaction
- FACS analysis was performed to determine transduction of HUT 78 cells with vector (PA317/G1MD.1-15) by a modification of the method described previously (Kessel et al., Cancer Res., Vol. 51, pgs. 4665-4670 (1991)). Cells were incubated at 37° C. for 20 min. then centrifuged at 1,500 rpm for 10 min. Cells were resuspended in basal medium and affluxed at 37° C. for 45 min. Cells were centrifuged and resuspended in HBSS (1 ⁇ 10 4 cells/ml). Flow cytometry was performed using an EPICS C Cytometer (Coulter, Hialeah, Fla.).
- the PCR was employed to screen for the presence of the G1MD1 retroviral sequence in HUT 78 cells after transduction. Genomic DNAs from cells subjected to G1MD1 transduction as well as untransduced cells were isolated using the Elu-Quik system (Schleicher & Schuell, Keene, N.H.).
- Each 100 ⁇ l reaction included 1 ⁇ g of genomic DNA using standard reaction conditions: 1.5 mM MgCl 2 , 0.2 mM dATP, 0.2 mM dGTP, 0.2 mM dCTP, 0.2 mM TTP, 50 mM KCl, 10 mM Tris-HCl, pH 7.3, 1 ⁇ M synthetic primers (MDR1), 0.01 units/ ⁇ l Perfect Match Polymerase Enhancer (Strategene, La Jolla, Calif.), and 0.025 units/ ⁇ l AmpliTaq DNA polymerase (Perkin-Elmer Cetus, Emeryville, Calif.). DNA was amplified using 30 cycles of 3-min. incubations at 94° C. followed by 61° C.
- MDR1 MDR1
- primers were derived from different exons (exons 4 and 6), which are assayed by greater than 23 kb of intervening sequence.
- the amplified fragments were separated by electrophoresis in a 1.4% agarose gel and visualized by ethidium bromide staining, and the size was determined using DNA molecular weight markers (GIBCO BRL, Grand Island, N.Y.).
- HUT 78 a human leukemia line that grows in suspension, HUT 78, was also transduced with and without centrifugation.
- HUT 78 cells were transduced with amphotropic vector PA317/G1MD.1-15, which can express the broad specificity efflux pump responsible for multidrug resistance (MDR1).
- FACS analysis shown in FIG. 3B demonstrates that centrifugation (19.5%) yielded approximately three timed more cells capable of rhodamine effluex than were obtained without centrifugation (5.6%).
- An efficient transduction method is a key component for clinical utilization in clinical trials.
- Most protocols incorporate a 37° C. incubation tempature for various transduction times.
- a novel transduction procedure has been developed using the combination of centrifugation and 32° C. overnight incubation. Centrifugation has been used for improved detection of other viruses, and chlamydia in clinical specimens (Ripa and Mardh Nongonococal Urethritis and Related Infections, Holmes, et al., eds., American Society for Microbiology, Washington, D.C., pgs. 323-327, 1977; Heggie and Huang, J. Virol. Methods, Vol 41, pgs.
- PBL peripheral blood lymphocytes
- TIL tumor infiltrating lymphocytes
- bone marrow cells bone marrow cells
- High titer vectors were produced from retroviral vector producer cells in various monolayer culture systems.
- Vector supernatant is clarified, and the volume of supernatant containing retroviral vectors was reduced 16 to 25 times with vector recovery ranging from 91% to 96% in a Millipore Pellicon tangential flow filtration system.
- vectors were purified by a two-step procedure including polyethylene glycol (PEG) preciipitation and sucrose gradient centriguation.
- the vector reocveries were from 100% to 110% by a standard vector titer assay. This suggests that the vector preparations do not contain free gp70 or empty viral particles which compete for virus binding sites with infectious retroviral vectors.
- the retroviral vectors upon recovery, may be lyophilized successfully.
- retroviral vectors for gene therapy can be produced efficiently, concentrated, purified, and stored in scale-up quantities, and subsequently allows one to transduce a variety of target cells with high efficiency.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to an efficient method, termed spin transduction, of transducing cells with retroviral vectors. Retroviral particles, suspended in a pharmaceutically acceptable carrier, are contacted with the cells to be transduced, and the mixture is centrifuged for a sufficient period of time to permit transduction. This method leads to a 3- to 15-fold increase in transduction efficiency, depending on the type of cells transduced.
Description
This is a Division of application Ser. No. 08/180,717 filed Jan. 12, 1994.
This invention relates to the purification of retroviral vectors. More particularly, this invention relates to a method of large scale purification of retroviral vector particles whereby one obtains improved recovery of retroviral vector particles from a culture of retroviral vector producer cells.
The number of human trials in human gene therapy continues to increase. In addition, preclinical studies in new approaches directed to human gene transfer similarly have increased. While several gene delivery systems with adenoviral vectors and liposomes have been studied, at present, retroviral vector systems account for the overwhelming number of published reports and human trials (Miller, et al., Mol. Cell. Biol., Vol. 6, pgs. 2895-2902 (1986); Danos, et al., PNAS, Vol. 85, pgs. 6460-6464 (1988). Muenchau, et al., Virology, Vol. 176, pgs. 262-265 (1990); Miller, Curr. Top. Microbiol. Immunol., Vol. 158, pgs. 1-24 (1992)). To date, the diseases under investigation involving the use of retroviral vectors for gene therapy include various types of cancer, genetic diseases (including adenosine deaminase deficiency, cystic fibrosis, and familial hypercholesteremia), and infectious diseases, specifically AIDS (Rosenberg et al., N. Engl. J. Med., Vol. 323, pgs. 570-578 (1990); Anderson, et al., Hum. Gene. Ther., Vol. 1, pgs. 331-362 (1990); Grossman, et al., J. Lab. Clin. Med., Vol. 119, pgs. 457-460 (1992); Riddel, et al., Hum. Gene, Ther., Vol. 3, pgs. 319-338 (1992)). At present, human trials are Phase I and/or II clinical trials to insure safety of the delivery system and the specific transgene. These early trials may also generate some meaningful information on efficacy.
In order to facilitate clinical applications of retroviral-mediated human gene transfer, retroviral vectors must be of high titer and free of detectable replication-competent retroviruses. However, it has been difficult to obtain large quantities of such retroviral vectors.
FIG. 1. Number of cells and vector titers of PA317/G1Na.40 producer cells grown in 75-cm2 flasks at different temperatures.
FIG. 2. Effect of temperature on viral particles per cell during 12 days of culture. PA317/G1Na.40 producer cells were grown in 75-cm2 flasks at 37 C., 34 C. and 32 C. Medium was changed every 24 hr. Cell number and vector titer were determined daily.
FIG. 3. A total of 1×106 cells in a 24-well plate were transduced with and without centrifugation (spun) at 2,500 rpm at 32° C. for 90 min. Cells were incubated overnight at 32° C. Three days after transduction the cells were prepared for PCR and FACS analyses. A. PCR agarose gel profile. Ethidium bromide-stained gel of amplification products obtained using primers specific for MDRI(1) or β-actin(2). Products were amplified from 1 μg of genomic DNA isolated from mock-transduced cells or cells transduced with PA317/G1MD1-15. The 100 bp ladder was obtained from GIBCO BRL. B. Flow cytometry (FACS analysis). Cells were harvested and suspended in basal DMEM containing 0.1 μg/ml rhodamine-123. Cells were incubated at 37° C. for 20 min., then centrifuged at 1,500 rpm for 10 min. Cells were resuspended in basal medium and effluxed at 37° C. for 45 min. Flow cytometry was performed by EPICS cytometer (Coulter).
It is an object of the present invention to provide a method for purifying retroviral vector particles whereby one obtains an increased amount of retroviral vector particles.
In accordance with an aspect of the present invention, there is provided a method of purifying retroviral vector particles. The method comprises culturing retroviral vector producer cells, which are capable of generating retroviral vector particles. A supernatant containing retroviral vector particles then is obtained from the culture of retroviral vector producer cells. The supernatant then is clarified, and then the clarified supernatant is concentrated after clarification. The concentrated supernatant then is contacted with a precipitation agent to form a precipitate containing the retroviral vector particles. The precipitate is recovered, and the recovered precipitate is suspended in a liquid. The retroviral vector particles are separated from the remainder of the precipitate by density gradient centrifugation. The separated retroviral vector particles then are recovered.
The above method enables one to obtain purified retroviral vector particles. The term "purified retroviral vectors particles" as used herein means a preparation of retroviral particles containing at least 80% by weight, preferably at least 85% by weight, and more preferably at least 90% by weight, of retroviral vector particles.
The retroviral vector producer cells may be cultured in any of a variety of monolayer culture systems. Such producer cells may be cultured in T-flasks, roller bottles, or bioreactors. The cells may be cultured in any acceptable culture medium such as, for example, AIM-V medium (Gibco BRL, Grand Island, N.Y.) containing 5% fetal bovine serum, or Dulbecco's modified Eagle medium (DMEM) with high glucose (4.5 g/l) supplemented with 10% heat-inactivated fetal bovine serum.
The producer cell line may be formed by transducing an appropriate packaging cell line with retroviral vectors. Examples of packaging cell lines which may be transduced include, but are not limited to, the PA317, PE501, Ψ-2, Ψ-AM, PA12, T19-14X, VT-19-17-H2, ΨRE, ΨCRIP, GPL, GP+E-86, GP+envAm12, and DAN cell lines. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO4 precipitation.
The cells generally may be cultured at a temperature of from about 32° C. to about 37° C. Most preferably, the cells are cultured at a temperature of about 32° C. At 32° C., the vector particles have a half-life of up to about 48 hours.
The viral supernatant, which is obtained from the culture of retroviral vector producer cells, and which may have a titer of, for example, from about 106 to about 107 CFU/ml, may be clarified by passing the supernatant through a filter means, such as a nominal type filter unit. The filter may have a pore size of from about 0.2μ to about 5.0μ, preferably from about 0.8μ to about 1.5μ. Most preferably, the filter has a pore size of about 1.2μ.
The clarified viral supernatant then may be concentrated by passing the clarified viral supernatant through a tangential flow filtration system. Preferably, the membrane in such system has a 300,000 molecular weight cutoff. Such a system may reduce the volume of supernatant containing retroviral vector particles by about 16 to 25 times, with vector recovery being at least 90%. An example of a tangential flow filtration system which may be employed in accordance with the present invention is a Millipore Pellicon tangential flow filtration system (Millipore, Bedford, Mass.) with a PLMK000C5 cassette (5 square feet, 300,000 NMWL). The system also may be equipped with a pump to exert a low membrane feed pressure of 5 psi. Such a concentrated viral supernatant may have a vector recovery of greater than 95% compared with the amount of vector present prior to concentration, and a vector titer of from about 107 to about 108 CFU/ml.
The concentrated viral supernatant then is contacted with a precipitation agent. In one embodiment, the precipitation agent is a polyalkylene glycol, such as, for example, polyethylene glycol. In a preferred embodiment, once the viral supernatant is contacted with the precipitation agent, the viral supernatant and the precipitation agent are centrifuged at a speed of from about 8,000×g to about 10,000×g to pellet precipitated material, which then is recovered. Such precipitate contains the retroviral vector particles. The recovered precipitate is suspended in a liquid, such as a buffer. The retroviral vector particles are separated from the remainder of the precipitate by density gradient centrifugation. Preferably, the suspended precipitate is subjected to sucrose gradient ultracentrifugation (discontinuous or preferably linear). More preferably, the ultracentrifugation is effected at a speed of from about 100,000×g to about 120,000×g. After centrifugation, the retroviral vector particles are recovered. Vector recovery may be greater than 95%, and vector titer may be from about 109 to about 1010 CFU/ml. An example of purifying viral supernatant by polyethylene glycol precipitation and sucrose gradient centrifugation is described in Syrewicz, et al., Appl. Microbiol., Vol. 24, pgs. 488-494 (1972), incorporated herein by reference.
The above purification steps enable one to recover an increased amount of retroviral vector particles. The resulting preparation containing the retroviral vector particles is free of components which may compete with the retroviral vector particles for binding sites located on target cells to which the retroviral vector particles may bind and infect. Such components include free gp70 protein and empty viral particles.
If desired, the retroviral vector particles recovered from the centrifugation step may be lyophilized and saved for future use. Such lyophilization may be carried out by adding to the retroviral vector supernatant solutions of glucose and/or sorbitol and gelatin in phosphate buffered saline. The samples then maybe frozen in a dry ice/acetone bath and then placed in a freeze dryer. When the retroviral vector particles are needed for gene therapy, the lyophilized retroviral vector particles may be reconstituted by adding an equal volume of sterile water. After reconstitution, vector recovery may be greater than 90%, and vector titer may be from about 109 to about 1010 CFU/ml.
The purified retroviral vector particles are used to transduce cells in vivo or ex vivo for purposes of gene therapy. For ex vivo transduction, the inventors have developed a novel preferred transduction method, which they call spin transduction. The particles, suspended in a pharmaceutically acceptable carrier, are contacted with the cells to be transduced, and the mixture is centrifuged for a sufficient period of time to permit transduction. The mixture is centrifuged at 1,000-4,000 rpm, preferably at 2,000-3,000 rpm, and most preferably at about 2,500 rpm for a period of time from about 30 minutes to 3 hours, preferably 1 to 2 hours, and most preferably about 90 minutes. The spin transduction is done at a tempreature of 15° C. to 37° C., preferably 20° C. to 35° C., and most preferably 32° C. This method leads to a 3- to 15-fold increase in transduction efficiency, depending on the type of cells transduced.
The invention now will be described with respect to the following example; however, the scope of the present invention is not intended to be limited thereby.
Unless noted otherwise, all viral vector titers of retroviral vectors carrying the neomycin resistance marker are determined by a G418 selection method using NIH 3T3 TK-cells as target cells. The assay procedure is as follows:
On day 1, NIH-3T3 TK-cells were seeded at 1×105 cells/well of a six-well tissue culture plate (Becton Dickinson, Lincoln Park, N.J.) and incubated at 37° C. in 5% CO2. On day 2, serial ten-fold dilutions of vector specimen in medium containing 8 μg/ml Polybrene were added to the target cells and incubated at 32° C. for an additional 24 hours. On day 3, the medium was removed and replaced with medium containing 800 μg/ml G418. Plates were incubated at 37° C. in 5% CO2. On day 6, plates were refed with medium containing 800 ug/ml G418. On day 8, colonies were stained with methylene blue and the vector titer was calculated as the number of colony forming units (cfu) per ml.
A. Formation of Producer Cell Lines.
The following producer cell lines were formed by transducing retroviral vectors including various desired genes and promoters (sometime hereinafter referred to as Gene 1, Gene 2, Promoter 1, and Promoter 2) into the PA317 amphotropic retrovirus packaging cell line (Miller, et al, Mol. Cell. Biol., Vol. 6, pgs. 2895-2902 (1986); Miller, et al., Biotechniques, Vol 7, pgs. 980-990 (1989), incorporated herein by reference), were formed by standard transduction techniques. The producer cell lines are given in Table I below:
TABLE I
______________________________________
Gene Promoter Gene Promoter
Producer cells
1 1 2 2
______________________________________
PA317/G1Na.40 Neo.sup.R
LTR -- --
PA317/G1Na.47 Neo.sup.R
LTR -- --
PA317/G1IL2RαSvNa.3
IL-2Rα
LTR Neo.sup.R
SV40
PA317/G1IL2RβSvNa.14
IL-2Rβ
LTR Neo.sup.R
SV40
PA317/G1NaCvI2G
Neo.sup.R
LTR IL-2 CMV
PA317/G1NaBcI2G.6
Neo.sup.R
LTR IL-2 β-Actin
PA317/G1βGsvna.29
lacZ LTR Neo.sup.R
SV40
PA317/G1NaSvnβg.2-1
Neo.sup.R
LTR lacZ SV40
PA317/G1NaSvnβg.2-12
Neo.sup.R
LTR lacZ SV40
PA317/GlnβGsvna.8-1
lacZ LTR Neo.sup.R
SV40
PA317/GlnβGsvna.8-3
lacZ LTR Neo.sup.R
SV40
PA317/G1NaSvAd.24
Neo.sup.R
LTR ADA SV40
PA317/LASN ADA LTR Neo.sup.R
SV40
PA317/G1F1SvNa.19c
IFN-α
LTR Neo.sup.R
SV40
PA317/G1NaCvF32.20
Neo.sup.R
LTR IFN-r CMV
PA317/G1T2SvNa.24
TNF-α
LTR Neo.sup.R
SV40
PA317/LT12SN.40
TNF-α
LTR Neo.sup.R
SV40
PA317/LNCT11.8
Neo.sup.R
LTR TNF-α
CMV
PA317/LNST11.20
Neo.sup.R
LTR TNF-α
SV40
PA317/G1MD.1-15
MDR1 LTR -- --
PA317/G1MD.S-5
MDR1 LTR -- --
PA317/LIXSN Factor IX
LTR Neo.sup.R
SV40
______________________________________
Producer cell line PA317/G1Na.40 is described in Miller, Curr. Top. Microbiol. Immunol., Vol. 158, pgs. 1-24(1992), incorporated herein by reference. Producer cell line PA317/LASN is described in Hock, et al., Blood, Vol. 74, pgs. 876-881 (1989), incorporated herein by reference. Producer cell line PA317/L1XSN is described in Palmer, et al., Blood, Vol. 73, pgs. 438-445 (1989), incorporated herein by reference.
B. Culturing of Producer Cells
PA317/G1Na.40 producer cells (2×106 cells) were inoculated in 75-cm2 flasks and were incubated at 37° C., 34° C., and 32° C. in 5% CO2 to determine the effect of incubation temperature on vector titer. The medium was changed every day.
The amphotropic retroviral vectors were assayed by a G418 selection method using NIH-3T3 TK- cells as target cells. On day 1, NIH-3T3 TK- cells were seeded at 1×105 cells/well of a six-well tissue culture plate (Becton Dickinson, Lincoln Park, N.J.) and incubated at 37° C. in 5% CO2. On day 2, serial ten-fold dilutions of vector specimen in medium containing 8 μg/ml Polybrene were added to the target cells and incubated at 32° C. for an additional 24 hr. On day 3, the medium was removed and replaced with medium containing 800 μg/ml G418. Plates were incubated at 37° C. in 5% CO2. On day 6, plates were refed with medium containing 800 μg/ml G418. On day 8, colonies were stained with methylene blue and the vector titer was calculated as the number of colony forming units (cfu) per ml.
The results are shown in FIG. 1. Cells grown at 37° C., 34° C., and 32° C. achieved 100% confluence on days 5, 6, and 8, respectively. Days 5, 6, and 8 also showed the highest vector titers for each of the three temperatures. Retroviral vector titers increased as temperature decreased. The highest vector titer of 1-day-old supernatant was always obtained from cells incubated at 32° C., 8.5×106 cfu/ml, and remained at that approximate level for 5 days. Cells incubated at 37° C. showed the lowest titer over 7 days. In the experiment shown in FIG. 1, the maximum titer difference between 32° C. and 37° C. was 1.5 logs on day 8. Vector from cells incubated at 34° C. yielded titers intermediate between 32° C. and 37° C. Interestingly, the highest number of cells (1.1×106) was obtained at 32° C. on day 12. During the experiment, viability of the cells for each temperature ranged between 92 and 98%.
The number of vector particles per cell was calculated by dividing the number of vector particles per milliliter determined in a standard titer assay by the number of cells from viability counts. As shown in FIG. 2, the 32° C. and 34° C. incubation temperatures showed a maximum of six vector particles per cell compared with a maximum of two vector particles per cell at 37° C. under the conditions of these calculations.
To determine the effect of CO2 on production of viral vectors, PA317/G1Na.40 cells were grown in 75-cm2 flasks and roller bottles with and without 5% CO2 in air. The titer of vector supernatants cultivated under both conditions revealed similar titers at the three incubation temperatures studied (data not shown). The results of these studies and those with other vectors suggest that endogenous CO2 from the cells support the cell growth and vector production without 5% exogenous CO2.
Producer cells were easily adapted to grow in 850-cm2 roller bottles. Cells maintained maximum confluence for at least 2 weeks. PA317/G1Na.40 and PA317/LT12SN.40 producer cells were grown in roller bottles and incubated at 37° C., 34° C., and 32° C. After the cells reached confluence, the medium was harvested daily. The vector titers shown in Table II below represent the titers reached after 100% confluence.
TABLE II
______________________________________
Vector Titers from Cells Grown in
Roller Bottles (850 cm.sup.2) at 37° C., 34° C., and
32° C.
Temperature
Vector 37° C.
34° C.
32° C.
______________________________________
PA317/G1Na.40
.sup. 2.9 × 10.sup.6b
4.7 × 10.sup.6
1.7 × 10.sup.7
(± 1 × 10.sup.6).sup.a
(± 1.4 × 10.sup.5)
(± 2.1 × 10.sup.6)
PA317/LT12SN.40
2.3 × 10.sup.6
1.2 × 10.sup.7
1.8 × 10.sup.7
(± 1 × 10.sup.5)
(± 2.0 × 10.sup.6)
(± 3.3 × 10.sup.6)
______________________________________
.sup.a Producer cells (2 × 10.sup.7) were seeded in roller bottles
and incubated at 37° C., 34° C., and 32° C. The
supernatant from producer cells were harvested after 100% confluence.
.sup.b Vector titer in 1day-old supernatant.
The titers from each temperature remained stable without significant change for the 2-week experimental time period. A significant increase of vector titer was achieved at 32° C. incubation temperature. The titer of PA317/G1Na.40 increased from 2.9×106 cfu/ml at 37° C. to 1.7×107 cfu/ml at 32° C. A significant increase in titer also was achieved with vector PA317/LT12SN.40, 2.3×106 cfu/ml at 37° C. to 1.8×107 cfu/ml at 32° C. The results of increased vector titer at 32° C. compared to 37° C. incubation for both 75-cm2 flasks (FIG. 1) and roller bottles (Table II) are statistically significant at the p<0.01 probability level.
Supernatants from PA317/G1Na.40 and PA317/LT12SN.40 producer cells grown in roller bottles were collected at 1- and 2-day intervals at 32° C. cultivation (Table III).
TABLE III
______________________________________
Vector Titers in 1-Day- and 2-Day-Old
Supernatants in Roller Bottles
1-Day-Old 2-Day-Old
Vector Supernatant
Supernatant
______________________________________
PA317/G1Na.40 .sup. 1.1 × 10.sup.7b
2.1 × 10.sup.7
(± 4.5 × 10.sup.6).sup.a.sup.
(± 4.9 × 10.sup.6)
PA317/LT12SN.40
3.1 × 10.sup.6
1.2 × 10.sup.7
(± 1.5 × 10.sup.5)
(± 1.5 × 10.sup.6)
______________________________________
.sup.a Producer cells were grown in roller bottle at 32° C. The
supernatants from producer cells were harvested at 100% cell confluence.
.sup.b Vector titer (CFU/ml).
The vector titer of 2-day-old supernatants from PA317/G1Na.40 and PA317/LT12SN.40 were approximately two times and four times higher than that of 1-day-old supernatants, respectively. The above results from 2-day-old supernatant collection at 32° C. incubation also were demonstrated using several of the other producer cell lines. Increased titers at lower temperature may be partially due to decreased vector inactivation at the lower temperature.
Roller bottles of different surface areas were compared for vector yield. As expected, the vector titer from supernatants of PA317/G1Na.40 and PA317/G1βGsvna.29 producer cell lines from a pleated roller bottle of 1,700-cm2 surface area were approximately twice that of the 850-cm2 roller bottle (Table IV).
TABLE IV
______________________________________
Vector Titers in Supernatants from Cells
Grown in Different Types of Roller Bottles at 32° C.
Type of Roller Bottle
Vector 850 cm.sup.2
1,700 cm.sup.2
______________________________________
PA317/G1Na.40 .sup. 1.2 × 10.sup.7b
2.6 × 10.sup.7
(± 3.5 × 10.sup.6).sup.a.sup.
(± 4.3 × 10.sup.6)
PA317/G1BgSvNa.29
4.2 × 10.sup.6
1.0 × 10.sup.7
(± 6.0 × 10.sup.5)
(± 3.5 × 10.sup.6)
______________________________________
.sup.a Producer cells were grown in roller bottles at 32° C.
Twoday-old supernatants were collected after 100% cell confluence.
.sup.b Vector titer (CFU/ml).
The number of cells counted at the end of the 2-week culture from a 1,700-cm2 roller bottle was approximately twice that counted from the 850-cm2 roller bottle (data not shown), suggesting that the vector yield per cell did not differ in the pleated and unpleated bottles. To date, the highest virus titer achieved was from a 2-day-old PA317/G1Na.40 supernatant from the pleated-type roller bottle incubated at 32° C., 1×106 cfu/ml. This has been repeated two times. Twenty-one of 22 different retroviral vector producer cells increased titers by a 2-day-old supernatant at 32° C. incubation. Vector LASN was the exception in this study.
C. Clarification of Viral Supernatant
The viral supernatant was harvested from the roller bottle by aspiration or pouring into a collection bottle. Immediately thereafter, the supernatant was clarified by pumping the supernatant through a 1.2μ nominal type polypropylene filter (Sartorius) to remove any debris and cells.
D. Concentration of Vector Supernatant
Vector supernatants from PA317/G1Na.40, PA317/LT12SN.40, and PA317/G1NaSvAd.24 producer cells were concentrated using the Millipore Pellicon tangential flow filtration system (Millipore, Bedford, Mass.) with a PLMK000C5 cassette (5 square feet, 300,000 NMWL). A pump was used to exert a low membrane feed pressure of 5 psi. Concentration was achieved within 30 minutes. To ensure high vector recovery, it is necessary to maximize the surface area of the membrane and minimize supernatant circulation with a low membrane feed pressure. As shown in Table V below, the volume of the supernatant was reduced from 16 to 25 times, and the vector titer increased from 15 to 24 times. Vector recovery ranged from 91% to 96%.
TABLE V
__________________________________________________________________________
Volume of
supernatant Titer
(ml) (cfu/ml)
Before
After
Volume
Before
After
Vector
Vector
Vector conc.
conc.
reduction
conc.
conc.
concen.
recovery
__________________________________________________________________________
PA317/G1Na.40
10,000
400
25X 1.7 × 10.sup.6
4.1 × 10.sup.7
24X 96%
PA317/LT12SN.40
10,000
500
20X 2.5 × 10.sup.6
4.5 × 10.sup.7
18X 91%
PA317/G1NaSvAd.24
8,000
500
16X 1.6 × 10.sup.6
2.4 × 10.sup.7
15x 94%
__________________________________________________________________________
E. Centrifugation of Vital Supernatant and Recovery of Retroviral Vectors Therefrom
The concentrated viral supernatant (from about 100 ml to about 200 ml) was mixed with a 1/10 volume of 4M NaCl on ice while stirring. Polyethylene glycol was added (8% w/v) slowly and stirred in ice for 3 hours. The precipitate was collected by centrifugation at 8,000×g for 15 minutes and resuspended in 0.01M tris (hydroxymethyl) aminomethane hydrochloride (TNE) pH7.5, 0.1M NaCl, and 0.001M ethylenediamine tetracetic acid (i.e., at from about 1/100 to 1/25 of the original supernatant volume).
The suspension was layered on a discontinuous sucrose gradient (20% and 55% w/w) in TNE and centrifuged in a Beckman SW-40Ti rotor at 100,000×g for 2 hours at 4° C.
After the centrifugation, the sharp virus band was observed. The virus band was collected by inserting a 21-gauge hypodermic needle into the centrifuge tube, and diluted ten-fold with TNE and stored at -70° C. Vector recovery was greater than 95% and vector titer was at least 109 CFU/ml.
F. Lyophilization of Retroviral Vectors
Lyophilization of retroviral vectors was performed using a Model Freeze Mobil Lyophilizer (Virtis, Gardiner, N.Y.). The additives, glucose, sorbitol, and gelatin, were prepared as 50%, 50%, and 25% solutions, respectively, in phosphate-buffered saline (PBS). The solutions were filtered through 0.22 μm filters. Aliquots of glucose (1 ml), sorbitol (1 ml), or sorbitol with gelatin (1 ml) were added to the viral supernatant (19 ml) derived from PA317/G1Na.40 producer cells. The samples were frozen quickly in 1.0 ml or 20 ml aliquots in a dry ice/acetone bath and placed in a freeze-dryer. The lyophilized material was stored at 4° C. Samples were reconstituted with an equal volume of sterile water.
Retroviral vectors were preserved after lyophilization and retained relatively high transducibility. As shown in Table VI below, samples without additives showed the lowest recovery rate, 21%. Specimens supplemented with glucose, sorbitol, or gelatin demonstrated a relatively low recovery rate (from 48% to 61%). The combination of glucose or sorbitol with gelatin, however, demonstrated a higher vector recovery rate (from 64% to 83%). The viral titer was from 2×106 cfu/ml to 3×106 cfu/ml after lyophilization.
TABLE VI ______________________________________ Recovery of PA317/G1Na.40 Vector After Lyophilization Additive VirusRecovery ______________________________________ None 21% 5% Glucose 61% 5% Sorbitol 58% 2.5% Gelatin 48% 5% Glucose/2.5% Gelatin 64% 5% Sorbitol/2.5% Gelatin 65% 5% Glucose/5% Sorbitol/2.5% Gelatin 83% ______________________________________
G. Transduction of Cells with Recovered Vector Supernatant
NIH3T3 TK- cells were seeded at 1×105 cells/well in a six-well plate as an adherent target cell line and incubated at 37° C. overnight to yield approximately a 60% confluent monolayer. A 10-fold serial dilution of vector supernatants (104, 10-5, and 10-6) containing 8 μg/ml Polybrene were added in duplicate to appropriate wells on day 2. The six-well plate was centrifuged at 2,500 rpm for 90 min. at 32° C. by using a plate holder in a Beckman GS-6KR centrifuge (Beckman, Fullerton, Calif.). After centrifugation, the plate was incubated at 32° C. overnight. On day 3, the wells were refed with 5 ml of medium containing 800 μg/ml G418. The plate was incubated at 37° C. for 3 days. On day 5, medium was replaced to remove dead cells. On day 8, G418-resistant colonies were stained and counted.
In additional experiments, HUT 78 cells, a human T-cell leukemia line, as a suspension target cell line, were transduced with an amphotrophic vector PA317/G1MD1-15 which carried the MDR1 gene encoding p-glycoprotein (Endicott, et al., Ann. Rev. Biochem., Vol. 58, pgs 137-171 (1989)).
Cells were seeded at 1×106 cells/well of a 24-well plate (Costar, Cambridge, Mass.). A higher number of HUT 78 cells were needed to cover the bottom of the well. Two milliliters of vector supernatant containing 8 μg/ml of Polybrene was added to each well. The plate was centrifuged at 2,500 rpm for 90 min. at 32° C. and incubated at 32° C. overnight. The next day the wells were refed with fresh medium and incubated at 37° C. for 3 days. Cells were collected and washed two times with Hank's balanced salt solution (HBSS) and assayed for rhodamine afflux pump by FACS analysis and for the MDR1 gene by polymerase chain reaction (PCR) assay. As a control, untransduced HUT 78 cells were assayed.
FACS analysis was performed to determine transduction of HUT 78 cells with vector (PA317/G1MD.1-15) by a modification of the method described previously (Kessel et al., Cancer Res., Vol. 51, pgs. 4665-4670 (1991)). Cells were incubated at 37° C. for 20 min. then centrifuged at 1,500 rpm for 10 min. Cells were resuspended in basal medium and affluxed at 37° C. for 45 min. Cells were centrifuged and resuspended in HBSS (1×104 cells/ml). Flow cytometry was performed using an EPICS C Cytometer (Coulter, Hialeah, Fla.).
The PCR was employed to screen for the presence of the G1MD1 retroviral sequence in HUT 78 cells after transduction. Genomic DNAs from cells subjected to G1MD1 transduction as well as untransduced cells were isolated using the Elu-Quik system (Schleicher & Schuell, Keene, N.H.). Each 100 μl reaction included 1 μg of genomic DNA using standard reaction conditions: 1.5 mM MgCl2, 0.2 mM dATP, 0.2 mM dGTP, 0.2 mM dCTP, 0.2 mM TTP, 50 mM KCl, 10 mM Tris-HCl, pH 7.3, 1 μM synthetic primers (MDR1), 0.01 units/μl Perfect Match Polymerase Enhancer (Strategene, La Jolla, Calif.), and 0.025 units/μl AmpliTaq DNA polymerase (Perkin-Elmer Cetus, Emeryville, Calif.). DNA was amplified using 30 cycles of 3-min. incubations at 94° C. followed by 61° C. and then by 72° C. To avoid detection of endogenous MDR1 genes, MDR1, primers were derived from different exons (exons 4 and 6), which are assayed by greater than 23 kb of intervening sequence. The amplified fragments were separated by electrophoresis in a 1.4% agarose gel and visualized by ethidium bromide staining, and the size was determined using DNA molecular weight markers (GIBCO BRL, Grand Island, N.Y.).
The effect of centrifugation of vector on target cell transduction was investigated. Nine different retroviral vectors were assayed for their ability to transduce NIH-3T3 TK cells with or without centrifugation. An increase in titer as dertermined by the number of G418-resistant colonies was observed in all experiments. Representative results are shown in Table VII. This method has now been used over 50 times with NIH-3T3 TK cells as the target cell. The titer increases in samples varied from 1 to 18-fold.
In addition to NIH-3T3 TK cells, a human leukemia line that grows in suspension, HUT 78, was also transduced with and without centrifugation. In this experiment, HUT 78 cells were transduced with amphotropic vector PA317/G1MD.1-15, which can express the broad specificity efflux pump responsible for multidrug resistance (MDR1). FACS analysis shown in FIG. 3B demonstrates that centrifugation (19.5%) yielded approximately three timed more cells capable of rhodamine effluex than were obtained without centrifugation (5.6%). Consistent with this result, amplification of MDR1 sequences in these cells by PCR revealed that cells transduced using centrifugation contained more G1MD proviral sequences than cells transduced without centrifugation (FIG. 3A), directly demonstrating that centrifugation leads to increased transduction efficiency.
TABLE 7
__________________________________________________________________________
COMPARISON OF VECTOR TRANSDUCTION ON NIH-3T3 TK.sup.- CELLS
WITH AND WITHOUT CENTRIFUGATION (2,500 rpm, 90 min)
Vector titer (cfu/ml).sup.a
Culture No Titer
methods
Producer cells
centrifugation
Centrifugation
increase
__________________________________________________________________________
Cell Cube
PA317/G1NaSvAd.24
2.0 × 10.sup.6
2.2 × 10.sup.7
11×
3.4 × 10.sup.6
2.7 × 10.sup.7
8×
2.6 × 10.sup.6
2.3 × 10.sup.7
9×
Roller bottle
PA317/G1Na.40
2.6 × 10.sup.7
2 × 10.sup.8
8×
PA317/G1NaSvAd.24
1.7 × 10.sup.6
1.1 × 10.sup.7
7×
1.1 × 10.sup.6
1.5 × 10.sup.7
14×
PA317/L1XSN
5.7 × 10.sup.5
5.5 × 10.sup.6
10×
PA317/G1F1SvNa.19c
6.0 × 10.sup.5
7.8 × 10.sup.6
13×
PA317/G1IL2RαSvNa.3
1.1 × 10.sup.6
1 × 10.sup.7
9×
PA317/G1IL2RβSvNa.4
2.0 × 10.sup.5
3.3 × 10.sup.6
17×
PA317/G1NaBcI2G.6
6.0 × 10.sup.5
9.5 × 10.sup.6
16×
PA317/G1T2SvNa.24
1.2 × 10.sup.5
7 × 10.sup.6
14×
T75 PE501/G1NaBcLa1
5 × 10.sup.5
1.8 × 10.sup.6
4×
__________________________________________________________________________
.sup.a Titers determined by G418 selection method.
An efficient transduction method is a key component for clinical utilization in clinical trials. Most protocols incorporate a 37° C. incubation tempature for various transduction times. A novel transduction procedure has been developed using the combination of centrifugation and 32° C. overnight incubation. Centrifugation has been used for improved detection of other viruses, and chlamydia in clinical specimens (Ripa and Mardh Nongonococal Urethritis and Related Infections, Holmes, et al., eds., American Society for Microbiology, Washington, D.C., pgs. 323-327, 1977; Heggie and Huang, J. Virol. Methods, Vol 41, pgs. 1-7, 1993) The combination of centrifugation and overnight transduction of NIH-3T3 TK- cells at 32° C. resulted in a 4- to 18-fold increase compared to the overnight transduction at 32° C. The actual mechanism for the success of this centrifugation method is not well understood; however, aggregation of vector particles and/or vector particles with debris may play a role. The supernatants from roller bottles and cCellCube appeared to be more viscous than supernatant from the 175 flask, although all supernatants were filtered through a 1.2 μm filter. Transduction by centrifugation on human leukemic HUT 78 cells also demonstrated a significant increase in trasnduction efficiency as determined by FACS and PCR analysis. This technique may result in a dramatic impact for successful gene therapy, especially where vector is in limited concentration. Studies of transduction on clinically relevant target cells such as peripheral blood lymphocytes (PBL), tumor infiltrating lymphocytes (TIL), bone marrow cells, and tumor cells are in progress.
H. Results and Discussion
High titer vectors were produced from retroviral vector producer cells in various monolayer culture systems. Vector supernatant is clarified, and the volume of supernatant containing retroviral vectors was reduced 16 to 25 times with vector recovery ranging from 91% to 96% in a Millipore Pellicon tangential flow filtration system. Subsequently, vectors were purified by a two-step procedure including polyethylene glycol (PEG) preciipitation and sucrose gradient centriguation. The vector reocveries were from 100% to 110% by a standard vector titer assay. This suggests that the vector preparations do not contain free gp70 or empty viral particles which compete for virus binding sites with infectious retroviral vectors. The retroviral vectors, upon recovery, may be lyophilized successfully.
In addition, the above example demonstrates a large-scale technology for retroviral vector production, as well as procedures for concentration, purification, and lyophilization of retroviral vectors, whereby one may obtain a purified composition having a high titer of retroviral vectors. This example demonstrates that retroviral vectors for gene therapy can be produced efficiently, concentrated, purified, and stored in scale-up quantities, and subsequently allows one to transduce a variety of target cells with high efficiency.
All publications cited herein are incorporated by reference.
It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may practiced other than as particularly described and still be within the scope of the accompanying claims.
Claims (10)
1. A method of transducing cells with retroviral vector particles, comprising:
(a) contacting a suspension of said retroviral vector particles with said cells to form a mixture of said retroviral vector particles and said cells; and
(b) centrifuging said mixture for a period of time sufficient to permit transduction.
2. The method of claim 1 wherein said mixture is centrifuged for a period of time of from 30 minutes to 3 hours.
3. The method of claim 1 wherein said mixture is centrifuged at from 1,000 to 4,000 rpm.
4. The method of claim 1 wherein said mixture is centrifuged at a temperature of from 15° C. to 37° C.
5. The method of claim 2 wherein said mixture is centrifuged for a period of time of from 1 hour to 2 hours.
6. The method of claim 5 wherein said mixture is centrifuged for a period of time of 90 minutes.
7. The method of claim 3 wherein said mixture is centrifuged at from 2,000 rpm to 3,000 rpm.
8. The method of claim 7 wherein said mixture is centrifuged at 2,500 rpm.
9. The method of claim 4 wherein said mixture is centrifuged at a temperature of from 20° C. to 35° C.
10. The method of claim 9 wherein said mixture is centrifuged at a temperature of about 32° C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/450,914 US5648251A (en) | 1994-01-12 | 1995-05-26 | Method of transduction of cells with retroviral vectors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18071794A | 1994-01-12 | 1994-01-12 | |
| US08/450,914 US5648251A (en) | 1994-01-12 | 1995-05-26 | Method of transduction of cells with retroviral vectors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18071794A Division | 1994-01-12 | 1994-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5648251A true US5648251A (en) | 1997-07-15 |
Family
ID=22661489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/450,914 Expired - Fee Related US5648251A (en) | 1994-01-12 | 1995-05-26 | Method of transduction of cells with retroviral vectors |
| US08/468,826 Expired - Fee Related US5661022A (en) | 1994-01-12 | 1995-06-06 | Purification of retroviral vectors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/468,826 Expired - Fee Related US5661022A (en) | 1994-01-12 | 1995-06-06 | Purification of retroviral vectors |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US5648251A (en) |
| EP (1) | EP0738319A4 (en) |
| JP (1) | JPH09508017A (en) |
| CA (1) | CA2181066A1 (en) |
| WO (1) | WO1995019427A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042820A1 (en) * | 1996-05-16 | 1997-11-20 | Duke University | Tristetraprolin |
| WO2008023770A1 (en) | 2006-08-23 | 2008-02-28 | Takara Bio Inc. | Baglike container for centrifugation and method of gene introduction using the same |
| US20100105124A1 (en) * | 1996-11-20 | 2010-04-29 | Hai Pham | Novel method for the production and purification of adenoviral vectors |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534423A (en) * | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
| US5811274A (en) * | 1994-12-09 | 1998-09-22 | The Regents Of The University Of Michigan | Methods, compositions and apparatus for cell transfection |
| AU4954496A (en) * | 1995-03-17 | 1996-10-08 | Hisamitsu Pharmaceutical Co., Inc. | Gene transfer preparation |
| JPH11505128A (en) * | 1995-05-22 | 1999-05-18 | カイロン コーポレイション | Chimeric integrase protein-mediated site-specific integration of vector constructs into eukaryotic genomes |
| CZ438398A3 (en) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Process for preparing recombinant adenoviruses |
| FR2750433B1 (en) * | 1996-07-01 | 1998-08-14 | Rhone Poulenc Rorer Sa | PROCESS FOR PRODUCING RECOMBINANT ADENOVIRUSES |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| DE69737107T2 (en) * | 1996-11-20 | 2007-07-12 | Introgen Therapeutics Inc., Austin | AN IMPROVED PROCESS FOR THE PRODUCTION AND CLEANING OF ADENOVIRAL VECTORS |
| CA2283641A1 (en) * | 1997-03-18 | 1998-09-24 | Introgene B.V. | Methods and compositions for genetically modifying primate bone marrow cells |
| US7276359B1 (en) * | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| EP1977764A1 (en) * | 1998-11-16 | 2008-10-08 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| ES2618851T3 (en) * | 2008-06-18 | 2017-06-22 | Oxford Biomedica (Uk) Limited | Purification of retroviral vectors |
| FR3014901B1 (en) | 2013-12-17 | 2017-06-09 | Genethon | PROCESS FOR PURIFYING ENHANCED VIRUSES OR VIRTORS |
| WO2015097650A1 (en) * | 2013-12-23 | 2015-07-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| WO2021119221A1 (en) * | 2019-12-10 | 2021-06-17 | Repligen Corporation | Methods of preparing viral vectors |
| TW202414636A (en) | 2022-06-16 | 2024-04-01 | 日商東京威力科創股份有限公司 | Substrate treatment device and substrate treatment method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753884A (en) * | 1986-01-28 | 1988-06-28 | Novagene, Inc. | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same |
| US4992051A (en) * | 1987-11-03 | 1991-02-12 | Novagene, Inc. | Infectious bovine rhinotracheitis virus mutants, methods for the production of same and methods for the use of same |
| US5075110A (en) * | 1988-06-30 | 1991-12-24 | Institut Merieux | Stabilizing vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173400A (en) * | 1983-09-15 | 1992-12-22 | Institut Pasteur | Antibody detection of antibodies to viral proteins in serum |
| GB8702816D0 (en) * | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| JPH02203783A (en) * | 1989-02-02 | 1990-08-13 | Banyu Pharmaceut Co Ltd | Cloned human t cell forming non-virulent aids virus having antigenicity |
| US5447859A (en) * | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
| US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
-
1995
- 1995-01-10 EP EP95908027A patent/EP0738319A4/en not_active Withdrawn
- 1995-01-10 WO PCT/US1995/000369 patent/WO1995019427A1/en not_active Ceased
- 1995-01-10 CA CA002181066A patent/CA2181066A1/en not_active Abandoned
- 1995-01-10 JP JP7519093A patent/JPH09508017A/en active Pending
- 1995-05-26 US US08/450,914 patent/US5648251A/en not_active Expired - Fee Related
- 1995-06-06 US US08/468,826 patent/US5661022A/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753884A (en) * | 1986-01-28 | 1988-06-28 | Novagene, Inc. | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same |
| US4992051A (en) * | 1987-11-03 | 1991-02-12 | Novagene, Inc. | Infectious bovine rhinotracheitis virus mutants, methods for the production of same and methods for the use of same |
| US5075110A (en) * | 1988-06-30 | 1991-12-24 | Institut Merieux | Stabilizing vaccines |
Non-Patent Citations (16)
| Title |
|---|
| Bodine, et al., Proc. Nat. Acad. Sci., vol. 87, pp. 3738 3742 (May 1990). * |
| Bodine, et al., Proc. Nat. Acad. Sci., vol. 87, pp. 3738-3742 (May 1990). |
| David A. Williams, "Expression of Introduced Genetic Sequences in Hemotopoietic Cells Following Retroviral-Mediated Gene Transfer" Human Gene Therapy, vol. 1, pp. 229-239, 1990. |
| David A. Williams, Expression of Introduced Genetic Sequences in Hemotopoietic Cells Following Retroviral Mediated Gene Transfer Human Gene Therapy, vol. 1, pp. 229 239, 1990. * |
| Fred D. Ledlez, "Clinical Considerations in the Design of Protocols for Somatic Gene Therapy", Human Gene Therapy, vol 2, pp. 77-83, 1991. |
| Fred D. Ledlez, Clinical Considerations in the Design of Protocols for Somatic Gene Therapy , Human Gene Therapy, vol 2, pp. 77 83, 1991. * |
| Kotane et al., "Improved Methods of Retroviral Vector Transduction and Production of Gene Therapy", Human Gene Therapy, vol. 5, pp. 19-28, 1994. |
| Kotane et al., Improved Methods of Retroviral Vector Transduction and Production of Gene Therapy , Human Gene Therapy, vol. 5, pp. 19 28, 1994. * |
| Moennig, et al., Virology, vol. 61, pp. 100 110 (1974). * |
| Moennig, et al., Virology, vol. 61, pp. 100-110 (1974). |
| Paul, et al., Human Gene Therapy, vol. 4, pp. 609 615 (1993). * |
| Paul, et al., Human Gene Therapy, vol. 4, pp. 609-615 (1993). |
| Rousculp, et al., Human Gene Therapy, vol. 3, pp. 471 477 (1992). * |
| Rousculp, et al., Human Gene Therapy, vol. 3, pp. 471-477 (1992). |
| Syrewicz, et al., Applied Microbiology, vol. 24, No. 3, pp. 488 494 (Sep. 1972). * |
| Syrewicz, et al., Applied Microbiology, vol. 24, No. 3, pp. 488-494 (Sep. 1972). |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042820A1 (en) * | 1996-05-16 | 1997-11-20 | Duke University | Tristetraprolin |
| US6187543B1 (en) | 1996-05-16 | 2001-02-13 | Duke University | Method of screening a compound for its ability to enhance the ability of tristetraprolin to inhibit tumor necrosis factor |
| US20100105124A1 (en) * | 1996-11-20 | 2010-04-29 | Hai Pham | Novel method for the production and purification of adenoviral vectors |
| US9428768B2 (en) * | 1996-11-20 | 2016-08-30 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| WO2008023770A1 (en) | 2006-08-23 | 2008-02-28 | Takara Bio Inc. | Baglike container for centrifugation and method of gene introduction using the same |
| US20100136680A1 (en) * | 2006-08-23 | 2010-06-03 | Hideto Chono | Baglike container for centrifugation and method of gene transfer using the same |
| EP2055767A4 (en) * | 2006-08-23 | 2012-11-07 | Takara Bio Inc | Baglike container for centrifugation and method of gene introduction using the same |
| US8815597B2 (en) | 2006-08-23 | 2014-08-26 | Takara Bio Inc. | Baglike container for centrifugation and method of gene transfer using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| US5661022A (en) | 1997-08-26 |
| JPH09508017A (en) | 1997-08-19 |
| CA2181066A1 (en) | 1995-07-20 |
| EP0738319A4 (en) | 2000-03-29 |
| EP0738319A1 (en) | 1996-10-23 |
| WO1995019427A1 (en) | 1995-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5648251A (en) | Method of transduction of cells with retroviral vectors | |
| Kotani et al. | Improved methods of retroviral vector transduction and production for gene therapy | |
| Mosca et al. | Mesenchymal stem cells as vehicles for gene delivery. | |
| EP0871754B1 (en) | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant | |
| WO1997021825A9 (en) | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant | |
| US6472212B1 (en) | Methods and compositions for genetically modifying primate bone marrow cells | |
| JP2000501614A (en) | Method for obtaining a retroviral vector supernatant having high transduction efficiency | |
| US20030157070A1 (en) | High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations | |
| Hennemann et al. | High-efficiency retroviral transduction of mammalian cells on positively charged surfaces | |
| US20200149065A1 (en) | Foamy viral vector compositions and methods for the manufacture of same | |
| JPH11514209A (en) | Highly efficient ex vivo transduction of hematopoietic stem cells with recombinant retrovirus preparations | |
| US5837536A (en) | Expression of human multidrug resistance genes and improved selection of cells transduced with such genes | |
| Fruehauf et al. | Protection of hematopoietic stem cells from chemotherapy-induced toxicity by multidrug-resistance 1 gene transfer | |
| CN117777314B (en) | Lentiviral vector and application thereof | |
| CA2275892A1 (en) | Nucleic acid constructs and uses thereof for direct nucleic acid incorporation into cells | |
| Izadpanah et al. | Gene delivery to mesenchymal stem cells | |
| EP0871756A2 (en) | High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations | |
| US6984379B1 (en) | Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood | |
| KR101100691B1 (en) | How to preserve retro viruses | |
| CA2283641A1 (en) | Methods and compositions for genetically modifying primate bone marrow cells | |
| Kwon et al. | High‐yield retroviral production using a temperature‐modulated two‐stage operation | |
| Mosca | Joseph D. Mosca, Ph. D.", J Kyle Hendricks, MS", Diana Buyaner, MS", Janice Davis-Sproul, BS", Lei-Chieh Chuang, MS", Manas K. Majumdar, Ph. D.", Rajesh Chopra, Ph. D.", Mark A. Thiede, Ph. D.", Uwe Junker, MD", Richard J. Rigg, Ph. D.", Sean P. | |
| US20020164800A1 (en) | Retroviral vector | |
| WO2001004332A1 (en) | Method to improve viral infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENETIC THERAPY, INC.;REEL/FRAME:013380/0550 Effective date: 20030124 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20090715 |